Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to Covid-19.

Veru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe Covid-19 infections.